

Special Pharmaceutical Benefits Program Advisory Council
Thursday, January 24, 2020
10:00 A.M. – 12:00 P.M.
Web Conference Call

Topic/Discussion	Action
<u>Introductions, Announcements & Updates:</u> John Haines	Began 10:10am
<p><u>Introductions:</u> SPBP Advisory Council Members, staff, and guests introduced themselves.</p> <p>Members Present: John Haines, Kathleen Brady, Carina Havenstrike, David Koren, Deb McMahon, Leah Magagnotti, Mimi McNichol, Meghan McNelly, Wayne Williams, Michael Witmer</p> <p>[Members Absent: Jerry Coleman, Rebecca Geiser, Margaret Hoffman-Terry, Angela Kapalko, Jeffrey Kirchner, Cindy Magrini, Rob Pompa, William Short, Arthur Williams, Heyzabeth Vaughn]</p> <p>Guests: Caroline Becker, Richard Smith, Nicole Reisner, Michael Hellman, Sarai Flores, S. Colon, Sejal Thanicutt, Lupe Diaz, Karen McCraw, Monique Allen, Casey Johnson, Daniel Yanick</p> <p>Department of Health Staff: Lindsey Pitten, Cheryl Henne, Kyle Fait, Sean Hoffman, Monisola Malomo, Kendra Parry</p> <p>University of Pittsburgh Staff: David Givens, Scott Arrowood</p>	10:10am
<p><u>Announcements/Updates:</u> John Haines</p> <ul style="list-style-type: none"> • Welcome new member Carina Havenstrite, Director of Medical Case Management with Wright Center for Community Health. • Next meeting for SPBP AC will be in person meeting at the Best Western Hotel in Harrisburg on Thursday, April 30th at 10am • Next Conference Call will be Thursday, July 30th at 10am. • Currently having issue with hotel scheduling for October in-person meeting and the dates will be either the 22nd or the 29th, please keep those open. • SPBP staffing has changed. Customer Service Rep, Sandy, had moved on and there is an opening. The Division of HIV/Care Section has a few openings including project officer overseeing regional grantees and new program manager for monitoring evaluation. Interviews are being conducted. • A few updates to SPBP website including the drug formulary that was updated Jan 1rst. Only minor changes from October. • We received recommendation to add link on our website that would allow people to sign up for an email distribution lists. Currently have internal distribution but will be exploring option for online sign-up. 	10:15am to 10:28 am

- Email sent notifying of SPBP Online Enrollment system rollout. In addition to case manager portal top enroll clients, physicians can upload documents, typically the HIV attestation form. Go to main page of MRx and click Provider Link and follow steps.
- Update on Medicaid back-filling and recovery process: Have solution developed to reclaim retroactive payments that were originally paid by SPBP. Looking to start process in first quarter 2020 and have it place by April for Jan-March claims.
- HRSA, funder for Ryan White grant, site visit for 3 days. Discussion for SPBP included how program runs, drug rebate process, types of drug covered, claims process, emergency plans, monitoring, Medicaid back-billing, payment of Medicare C and D premiums. Findings include both legislative findings (cited for contractor monitoring of department of Aging and Medicaid back-billing) and programmatic findings (continuity of operations plan). Strengths mentioned were ability to enroll 100% clients within 3 business days, the drug formulary, the amount of drugs covered, and ability to collect 40B rebates on nearly all eligible.


Approval of previous minutes

10:28am to 10:30am


Due to some technical issues with audio interference. John requested anyone to email him changes to minutes that were needed for October Meeting Minutes. Minutes assumed approved unless John receives notice after the close of the meeting.

Data & Quality Management Update: Sean Hoffman

10:30am-10:43am



- Percentage of clients with case managers has been consistently dropping over the last five quarters. It's a trend to keep an eye on; however, the case management portal, allowing clients and case managers to register each other, should help see these numbers start to rise.
- There is traditional drop-off of claims in last quarter as people meet their deductibles and make less claims. BIKTARVY is top drug followed by GENVOYA and TRIUMEQ



- In fourth quarter 2018, only 14% disenroll in first 6 months, but have 32% disenrollment in 7-12 months (not great but an improvement)
- March – December 2019 Call Center Data: 11, 685 calls. Average wait time for connection: 1 min. Average call time 2:27 min
- ADR is due first Monday in June.

Fiscal Update: Lindsey Pitten

Funding	FY 2018-19
SPBP Grant Award	\$28,064,078
Part B Grant Award	\$10,617,820
Carry-over 2017	\$10,074,578
Rebates	\$65,806,768
TPLs	\$3,508,447
State Appropriation	\$0
Total Funding	\$118,071,691

Expenditures	FY 2018-19
Drug Claims	\$74,569,880
Claims Admin	\$1,798,579
Medicare Claims (Parts C & D)	\$808,494
RW Grant Admin	\$3,438,017
RW Lab Testing	\$310,067
Regional Expenditures	\$17,877,019
Total Expenditures	\$98,802,056

Funding	FY 2019-20
SPBP Grant Award	\$27,711,308
Part B Grant Award	\$10,726,651
Carry-over 2018	\$0
Rebates	\$68,589,324
TPLs	\$8,778,646
State Appropriation	\$0
Total Funding	\$115,805,928

Expenditures	FY 2019-20
Drug Claims	\$23,862,134
Claims Admin	\$0
Medicare Claims (Parts C & D)	\$0
RW Grant Admin	\$1,884,561
RW Lab Testing	\$150,231
Regional Expenditures	\$671,511
Total Expenditures	\$26,568,436

- Still spending rebate 2018 Grant Year that was committed throughout 2019. Received \$10 million carryover request and now expenditures is closer to total funding.
- Overview of 2019 Grant Year: still spending rebate from 2018 so have a way to go to match expenditures to total funding.


10:44am-10:50am

Outreach Initiatives & MAI Update: Kyle Fait

- HPG activity: Next meeting is Feb 12-13 at Best Western Premier.
 - Main agenda is new member orientation; for 12 new members.
 - Subcommittees will meet and be introduced to new members.
 - New Co-chair, Rob Pompa, will begin. Thank you to Mike Hellman for his work as the former Co-chair.
 - Have 28 members with 25 expected to attend.
 - Working on Winter Bulletin, being put together by Pitt Staff.

10:50am-11:05am

- Next Stakeholder Townhall Meeting in Erie, PA, and held at Ambassador Banquet & Conference Center on Wednesday June 3 (2-6:45pm) and Thursday June 4 (8-am-1pm).
 - First day Townhall will be similar to last year. Second day will be HPG meeting with locals invited to observe.
 - Still working on location and date for September Townhall.
- Stigma/Discrimination Survey: a collaboration between SPBP, University of Pitt, and Pa DOH.
 - Purpose to understand experience of stigma and discrimination in healthcare settings. Information will be used in planning and development of services.
 - Timeline still to be determined but SPBP AC will be notified in advance.
- 5 Year Spend Plan
 - Media campaign: mini campaign ran Dec 9-20 in Pittsburgh and Philadelphia markets (to finish off media campaign funds). Still waiting for reports on the 2019 media campaigns. Currently planning for an RFP for 2020-2023 continuation of campaign.
 - HIV Summit on September 30th 2020 at Best Western Premier in Harrisburg. Looking for 200 attendees for one-day conference. May have larger conference in 2021.
- Will be transferring from PA NEDSS to a NEDSS Space system through the CDC. Planning is underway.
- Minority AIDS Initiative Update (MAI) Program year finishes at end of March. Final report to come.
 - Next MAI learning to be held in Harrisburg.
- SPBP Brochure update based on suggestions from prior meetings including additional QR codes, a breakout of the income, and drug coverage list.



Subcommittee Reports and Discussion: Margaret Hoffman-Terry not available for meeting. John Haines introduced Additions and Exclusions

11:05am-11:10am

Drug Formulary & Lab Services

SPBP
New Drug Additions - 3Q 2019

DRUG NAME	DESCRIPTION	FORMULARY DESCRIPTION	GROUP
XENLETA	lefamulin	ANTIBIOTICS	Treatment of community acquired pneumonia. Oral tablet and solution. All other antibiotics are covered.
NAYZILAM	midazolam	ANTICONVULSANTS	Treatment of acute intermittent seizures. Intranasal. All other anticonvulsants are covered.
INREBIC	fedratinib	ANTINEOPLASTIC AGENTS	Treatment of myelofibrosis. Oral tablet. All other antineoplastics are covered.
KANJINTI	trastuzumab-emms	ANTINEOPLASTIC AGENTS	Treatment of breast or gastric cancer. IV. All other antineoplastics are covered.
MVASI	bevacizumab-awwb	ANTINEOPLASTIC AGENTS	Treatment of cervical, colorectal, glioblastoma, lung, ovarian, and renal cancers. IV All other antineoplastics are covered.
ROZLYTREK	entrectinib	ANTINEOPLASTIC AGENTS	Treatment of non-small cell lung cancer and solid tumors. Oral cap. All other antineoplastics are covered.
TURALIO	peixidartinib	ANTINEOPLASTIC AGENTS	Treatment of tenosynovial giant cell tumor. Oral cap. All other antineoplastics are covered.
XPOVIO	selinexor	ANTINEOPLASTIC AGENTS	Treatment of multiple myeloma. Oral tablet. All other antineoplastics are covered.
VYNDAMAX	tafamidis	CARDIOVASCULAR AGENTS	Treatment of amyloid cardiomyopathy. Oral capsule. All other cardiovascular agents are covered.
ANNOVERA	segesterone	CONTRACEPTIVES	Contraception. Vaginal ring. All other contraceptives are covered.
SLYND	drospranone	CONTRACEPTIVES	Contraception. Oral tablet. All other contraceptives are covered.
BACSIMI	glucaagon	DIABETIC AGENTS	Treatment of hypoglycemia. Intranasal. All other diabetic agents covered.
GVOKE HYPOPEN	glucaagon	DIABETIC AGENTS	Treatment of hypoglycemia. SQ injection. All other diabetic agents covered.
GVOKE SYRINGE	glucaagon	DIABETIC AGENTS	Treatment of hypoglycemia. SQ. All other diabetic agents covered.
MYXREDLIN	insulin regular	DIABETIC AGENTS	Treatment of diabetes mellitus. Insulin - IV solution. All other diabetic agents covered.
ENZADYNE	lipase	DIGESTIVE ENZYMES	Treatment of exocrine pancreatic insufficiency. Capsules. All other digestive enzymes are covered.
QUINIXIL	mometasone furoate	GLUCOCORTICOIDS	Treatment of dermatoses. Topical cream. All other corticosteroids are covered.
EZALLOR SPRINKLE	rosuvastatin	LIPID LOWERING AGENTS	Treatment of hypertriglyceridemia, dysbetalipoproteinemia, and reduction of lipid in familial hypercholesterolemia. Oral sprinkle capsule. All other lipid lowering agents covered.
RINVOO ER	upadacitinib	MISCELLANEOUS RHEUMATOLOGICAL AGENTS	Treatment of rheumatoid arthritis. Oral tablet. All other RA meds covered.
SUNOSI	soriamfetol	STIMULANTS AND RELATED AGENTS	Treatment of daytime sleepiness in narcolepsy or obstructive sleep apnea. Oral tablet. All other CNS stimulants are covered.

SPBP
New Drug Exclusions - 3Q 2019

DRUG NAME	DESCRIPTION	GROUP
VYLEESI	bremelanotide	Indicated for hypoactive sexual desire disorder. SQ injection. Sexual dysfunction treatments are not covered.

- New Drug Additions and Exclusions were posted.
 - No comments or questions; Kathleen made motion to approve as-is. Wayne seconds. List was approved with no opposed or abstains

Mike Hellman: The Board for the PA Pharmacists Association unanimously voted to pursue PrEP without a prescription and their first effort will be to initiate discussion with Dr. Rachel Levine on the topic.

11:10am-11:18am

Question: How and when will new brochures be distributed? Answer: Will reach out through distribution lists to find out how many needed in English and Spanish

Adjourn